Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


2 Ann Oncol
2 Clin Cancer Res
5 Gynecol Oncol
1 Int J Oncol
1 Lancet Oncol
1 Oncogene
1 Oncol Rep
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Oncol

  1. OSKAY-OZCELIK G, Alavi S, Richter R, Keller M, et al
    EXPRESSION III: Patient s Expectations and Preferences regarding Physician-Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.
    Ann Oncol. 2018 Feb 5. pii: 4838337. doi: 10.1093.
    PubMed     Text format     Abstract available

  2. BANERJEE S, Oza AM, Birrer MJ, Hamilton EP, et al
    Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Ann Oncol. 2018 Feb 1. pii: 4833235. doi: 10.1093.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  3. LEE JM, Peer CJ, Yu M, Amable L, et al
    Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Clin Cancer Res. 2017;23:1397-1406.
    PubMed     Text format     Abstract available

  4. MONTFORT A, Pearce OM, Maniati E, Vincent B, et al
    A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0081.2016.
    PubMed     Text format     Abstract available

    Gynecol Oncol

  5. NAUMANN RW, Brown J
    Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Gynecol Oncol. 2018 Feb 1. pii: S0090-8258(18)30068.
    PubMed     Text format     Abstract available

  6. NITECKI R, Diver EJ, Kamdar MM, Boruta DM 2nd, et al
    Patterns of palliative care referral in ovarian cancer: A single institution 5year retrospective analysis.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30056.
    PubMed     Text format     Abstract available

  7. SWANSON CL, Kumar A, Maharaj JM, Kemppainen JL, et al
    Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30072.
    PubMed     Text format     Abstract available

  8. MILLER KR, Patel JN, Zhang Q, Norris EJ, et al
    HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30061.
    PubMed     Text format     Abstract available

  9. KESSOUS R, Octeau D, Klein K, Tonin PN, et al
    Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30055.
    PubMed     Text format     Abstract available

    Int J Oncol

  10. XU M, Xiao J, Chen M, Yuan L, et al
    miR1495p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway.
    Int J Oncol. 2018 Jan 24. doi: 10.3892/ijo.2018.4252.
    PubMed     Text format     Abstract available

    Lancet Oncol

    HIPEC improves survival in stage III epithelial ovarian cancer.
    Lancet Oncol. 2018 Jan 26. pii: S1470-2045(18)30065.
    PubMed     Text format    


  12. LADANYI A, Mukherjee A, Kenny HA, Johnson A, et al
    Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
    Oncogene. 2018 Feb 5. pii: 10.1038/s41388-017-0093.
    PubMed     Text format     Abstract available

    Oncol Rep

  13. ZHONG A, Zhang H, Xie S, Deng M, et al
    Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
    Oncol Rep. 2018 Jan 22. doi: 10.3892/or.2018.6229.
    PubMed     Text format     Abstract available

    PLoS One

  14. ZHANG R, Pu W, Zhang S, Chen L, et al
    Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial.
    PLoS One. 2018;13:e0191756.
    PubMed     Text format     Abstract available

  15. SINGH G, Roy J, Rout P, Mallick B, et al
    Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers.
    PLoS One. 2018;13:e0190485.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.